[Betahistine treatment of Menière's disease (author's transl)].
H Chüden
Abstract
H Chüden
Abstract
An evaluation of Betahistine hydrochloride treatment of 92 patients suffering from Menière disease and Menière-like syndrom is presented. Observed for more than one year 54 (89%) patients showed complete relief of vertigo-attack symptoms. 7 (12%) patients showed a distinct improvement in their hearing as reflected in their audiograms, only 7 (12%) patients showed a further loss of hearing. There appeared to be a trend toward further improvement when therapy was maintained over at least a period of 3--4 month. Vertigo seemed to be the symptom most responsive to treatment and tinnitus the most resistant. Minimal side effects were observed in 17 (18%) patients.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
An evaluation of Betahistine hydrochloride treatment of 92 patients suffering from Menière disease and Menière-like syndrom is presented. Observed for more than one year 54 (89%) patients showed complete relief of vertigo-attack symptoms. 7 (12%) patients showed a distinct improvement in their hearing as reflected in their audiograms, only 7 (12%) patients showed a further loss of hearing. There appeared to be a trend toward further improvement when therapy was maintained over at least a period of 3--4 month. Vertigo seemed to be the symptom most responsive to treatment and tinnitus the most resistant. Minimal side effects were observed in 17 (18%) patients.
Key concepts: Betahistine, Meniere's disease, Tinnitus, Vertigo, Medicine, Audiogram, MENIERE DISEASE, Hearing loss